Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Fredun PharmaceuticalsBOM:539730 +6.59%77 Days Payable is 51.20 as of Mar. 2026, which is 63% below its 10-year median of 139.31. GuruFocus rates BOM:539730 with a GF Score™ of 77/100 and a GF Value™ of ₹1,591.19 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 927 Drug Manufacturers companies, Fredun Pharmaceuticals ranks worse than 52.43% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Fredun Pharmaceuticals's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fredun Pharmaceuticals Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Fredun Pharmaceuticals's Days Payable distribution charts can be found below:
* The bar in red indicates where Fredun Pharmaceuticals's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Fredun Pharmaceuticals's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fredun Pharmaceuticals (BOM:539730) has a Days Payable of 51.20 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Fredun Pharmaceuticals and its competitors. This is 63% below median its historical median of 139.31. Over the past decade, Fredun Pharmaceuticals' Days Payable has ranged from 81.57 to 267.12. According to the industry distribution chart, Fredun Pharmaceuticals ranks #486 out of 927 companies in the Drug Manufacturers industry, placing it in the top 52.4%.
Is Fredun Pharmaceuticals' Days Payable too high?
Fredun Pharmaceuticals' current Days Payable of 51.20 is 63% below median its 10-year median of 139.31. Over the past 10 years, this metric has ranged from a low of 81.57 to a high of 267.12. The Drug Manufacturers industry median Days Payable is 90.38. Fredun Pharmaceuticals' value of 51.20 is 43.4% below this industry median. Based on the distribution chart, Fredun Pharmaceuticals ranks #486 out of 927 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Fredun Pharmaceuticals has a GF Score™ of 77/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Fredun Pharmaceuticals' Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Fredun Pharmaceuticals ranks #486 out of 927 companies for Days Payable. This places Fredun Pharmaceuticals in the lower half of its industry. The industry median Days Payable is 90.38. Fredun Pharmaceuticals' value of 51.20 is 43.4% below this benchmark. Historically, Fredun Pharmaceuticals' own Days Payable has ranged from 81.57 to 267.12 over the past decade. While the company's 10-year median is 139.31 vs. the industry median of 90.38, Fredun Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.38, based on 927 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fredun Pharmaceuticals's current Days Payable of 51.20 is 43.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Fredun Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fredun Pharmaceuticals's current Days Payable is 51.20, which is 63% below median its own 10-year median of 139.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fredun Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Fredun Pharmaceuticals (BOM:539730) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹1,591.19, compared to a current price of ₹2,753.70 — trading 73.1% above its estimated fair value. The current Days Payable is 51.20, which is 63% below median its 10-year median of 139.31 and 43.4% below the Drug Manufacturers industry median of 90.38. Fredun Pharmaceuticals' overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Fredun Pharmaceuticals (BOM:539730), the current Days Payable is 51.20 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fredun Pharmaceuticals (BOM:539730) Overvalued in 2026?
Based on GuruFocus' analysis, Fredun Pharmaceuticals stock appears to be overvalued.
The current stock price of ₹2,753.70 is trading 73.1% above its estimated GF Value™ of ₹1,591.19.
GuruFocus considers Fredun Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for BOM:539730:
Days Payable: 51.20 (63% below median its 10-year median of 139.31)
GF Value™: ₹1,591.19 vs. price of ₹2,753.70 (73.1% above fair value)
Industry Position: 43.4% below the Drug Manufacturers median (#486 of 927)
No single metric tells the full story. See the BOM:539730 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fredun Pharmaceuticals Ltd in its Endeavour to move ahead has now ventured into manufacturing of dietary /herbal supplements, nutraceuticals, and other healthcare products along with Animal Healthcare products also with products ranging from allopathic formulations to on field diagnostic kits, Company's main objective is to be a holistic healthcare provider. The group is dedicated to improving lives of people. The Company operates only in a single segment i.e. Pharmaceutical Segment. The company has presence in Domestic as well as International market. The company generates majority of revenue from Domestic market.
77GF Score
Get the complete analysis for BOM:539730
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:539730 has been successfully added to your 
